Claims for Patent: 8,673,339

Summary for Patent: 8,673,339

Title:	Demand-release bioactive composition for implantable medical devices
Abstract:	A biostable polymeric substrate of an implantable medical device unit includes a demand-release bioactive composition including one or more bioactive agents covalently bound to surface-modifying end groups of the substrate. Certain cellular activities, in proximity to the polymeric substrate, release substances reacting with the end groups such that the end groups release the one or more bioactive agents, which modify the certain cellular activities.
Inventor(s):	Stokes; Kenneth B. (Anoka, MN), Ebert; Michael J. (Fridley, MN), Hobot; Christopher M. (Tonka Bay, MN)
Assignee:	Medtronic, Inc. (Minneapolis, MN)
Application Number:	10/386,967
Patent Claims:	1. A medical device comprising: an implantable unit comprising a bulk polymeric material including surface-modifying end groups provided throughout the bulk of the polymeric material; and a demand-release bioactive composition provided within and throughout the bulk of the polymeric material included in the implantable unit, wherein the demand-release bioactive composition includes one or more bioactive agents covalently bound to the surface-modifying end groups, wherein the one or more bioactive agents are released when the surface-modifying end groups undergo one of oxidation, acid-catalyzed hydrolysis, or enzyme-catalyzed hydrolysis; wherein certain cellular activities, in proximity to the polymeric substrate, release substances reacting with the surface-modifying end groups such that the surface-modifying end groups release the one or more bioactive agents, which modify the certain cellular activities; wherein the cellular activities are initiated by macrophage activation; and wherein the one or more bioactive agents are only released when the surface-modifying end groups undergo oxidation, acid-catalyzed hydrolysis, or enzyme-catalyzed hydrolysis following macrophage activation, wherein the surface-modifying end groups are hydrolytically stable and oxidizable, wherein the surface modifying end group comprises polymethylene oxide, and wherein the one or more bioactive agents are bound to the polymethylene oxide. 2. The medical device of claim 1, wherein the implantable unit includes an intra-vascular portion. 3. The medical device of claim 1 wherein the polymeric material is a biostable polymeric material; and wherein the one or more bioactive agents comprises one or more bioactive anti-inflammatory agents. 4. The medical device of claim 3, wherein the implantable unit includes an intra-vascular portion. 5. The medical device of claim 1, wherein the one or more bioactive agents comprises an enzyme. 6. The medical device of claim 1, wherein the one or more bioactive agents comprises collagenase. 7. The medical device of claim 1, wherein the one or more bioactive agents comprises an anti-inflammatory agent. 8. The medical device of claim 3, wherein elevation of acute and chronic stimulation thresholds is avoided without the use of a monolithic controlled release device. 9. The medical device of claim 1, wherein elevation of acute and chronic stimulation thresholds is avoided without the use of a monolithic controlled release device. 10. The medical device of claim 1, wherein upon consumption of surface-modifying end groups at the surface of the polymeric material, additional surface-modifying end groups migrate from the bulk of the polymeric material to the surface of the polymeric material. 11. A medical device comprising: an implantable unit; a biostable polymeric substrate at least partially covering the unit and including surface-modifying end groups; and a demand-release bioactive composition comprising one or more bioactive agents covalently bound to the surface-modifying end groups; wherein the surface-modifying end groups are hydrolytically stable and oxidizable, such that cellular activities that occur in proximity to the polymeric substrate release substances that react with the surface-modifying end groups causing the surface-modifying end groups to release the one or more bioactive agents, which modify the certain cellular activities upon their release; wherein the cellular activities are initiated by macrophage activation; and wherein the surface modifying end groups are configured to release the one or more bioactive agents when the surface-modifying end groups undergo oxidation following macrophage activation, wherein the surface modifying end groups comprise polymethylene oxide, and wherein the one or more bioactive agents are bound to the polymethylene oxide. 12. The medical device of claim 11, wherein the one or more bioactive agents comprises an anti-inflammatory agent.

Details for Patent 8,673,339

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-02-26